Stuart Weisbrod’s Iguana Healthcare Management Is Fond of These Stocks
New York City-based Iguana Healthcare Management was founded by Stuart Weisbrod in 2010.
Posts Tagged ‘Amgen Inc (AMGN)’
Is PowerShare Buyback Achievers Fund a Buy? The Safest Way To Profit From $455 Billion In Stock Buybacks
Over the past few years at StreetAuthority, we've been chronicling the remarkable pace of share buybacks.
Amgen, Inc. (AMGN)’s Potential Promise
Last Friday, Zacks released a new report were it reconfirmed its neutral rating for Amgen, Inc. (NASDAQ:AMGN).
Omthera Pharmaceuticals Inc (OMTH), Elan Corporation, plc (ADR) (ELN), Onyx Pharmaceuticals, Inc. (ONXX): 3 Big Biotech Buyouts of 2013
The Chinese calendar says 2013 is the year of the snake, but the market says it's the year of biotech.
Amgen, Inc. (AMGN), Impax Laboratories Inc (IPXL): Keryx Biopharmaceuticals (KERX)’s Stifel Conference Presentation
There were definitely some good parts in what Keryx Biopharmaceuticals (NASDAQ:KERX) had to say at this week's Stifel Nicolaus Weisel Healthcare Conference in Boston.
Bristol Myers Squibb Co. (BMY), Merck & Co., Inc. (MRK): Is AstraZeneca plc (ADR) (AZN)’s Recent Acquisition Bigger Than Onyx?
AstraZeneca plc (ADR) (NYSE:AZN) may have missed out on acquiring the oncology platform of Onyx Pharmaceuticals, but it responded by pulling the trigger on a $500 million deal...
Amgen, Inc. (AMGN), Teva Pharmaceutical Industries Ltd (ADR) (TEVA): The Neulasta Question
In a couple of years, Amgen, Inc. (NASDAQ:AMGN) will have to face the music when the patent for its $4 billion a year drug, Neulasta, expires in the U.S. and Europe.
Aegerion Pharmaceuticals, Inc. (AEGR): Cheers and Jeers for Amgen, Inc. (AMGN)’s Pipeline
Just after the successful acquisition of Onyx Pharmaceuticals and positive results on AMG-145, a cholesterol-lowering experimental drug, Amgen, Inc.
Pfizer Inc. (PFE), Regeneron Pharmaceuticals Inc (REGN), Amgen, Inc. (AMGN): Invest in the Next Biotech Frontier
The last several months have been remarkably exciting in the biotech space.
Cytokinetics, Inc. (CYTK), Amgen, Inc. (AMGN): Digging Deeper Into This Heart Failure Drug’s Miss
Before the market opened last Tuesday, Cytokinetics, Inc. (NASDAQ:CYTK) and Amgen, Inc.
Alexion Pharmaceuticals, Inc. (ALXN), Amgen, Inc. (AMGN), Baxter International Inc. (BAX): The Treatment of Rare Diseases Offers Unique Opportunities
A company with a modus operandi of tackling rare and very rare diseases might not necessarily jump out as a great investment, but this company has banked more than a billion...
MiMedx Group Inc (MDXG), Cytokinetics, Inc. (CYTK), Amgen, Inc. (AMGN): A Trio of Horrendous Health-Care Stocks This Week
College football arrived in a big way over the past week or so, with plenty of big plays already.
Astex Pharmaceuticals, Inc. (ASTX) Becomes the Latest Biotech Domino to Fall
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) is being scooped up by Tokyo-based Otsuka Pharmaceuticals.
Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): Two Reasons This Biotech Hardly Moved After a Successful Trial
Adding Esperion Therapeutics' ECT-1002 to Pfizer Inc. (NYSE:PFE)'s Lipitor lowered bad LDL cholesterol levels by 22%.
Eli Lilly & Co. (LLY), Amgen, Inc. (AMGN), Merck & Co., Inc. (MRK): Where We’re Headed
Over the past couple of months we've discussed many of the biggest risk factors associated with some of the leading causes of death in the United States -- heart disease, cancer...
Amgen, Inc. (AMGN), Astex Pharmaceuticals, Inc. (ASTX), Pharmacyclics, Inc. (PCYC): This Week in Biotech
With the SPDR S&P Biotech Index up 35% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Celgene Corporation (CELG), Cytokinetics, Inc. (CYTK), Astex Pharmaceuticals, Inc. (ASTX): Is the Biotech Bubble About to Burst?
"Bubble" can be a provocative word in investing circles. Think of all that comes to mind when you hear it -- perhaps other words like over-hyped, overvalued, risky, etc.
Amgen, Inc. (AMGN), Onyx Pharmaceuticals, Inc. (ONXX): Monday’s Best Stocks
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Amgen, Inc. (AMGN), Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Onyx Pharmaceuticals, Inc. (ONXX): This Biotech Envisions Green
After a second offer, Amgen, Inc. (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc.
The Amgen, Inc. (AMGN)-Onyx Pharmaceuticals, Inc. (ONXX) Deal Should Make All Biotech Investors Happy
While that's certainly not what Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) investors were hoping for -- at one point, after Amgen, Inc.
Amgen, Inc. (AMGN), Onyx Pharmaceuticals, Inc. (ONXX), NASDAQ OMX Group, Inc. (NDAQ): Deals, Not Data, Drive Dow Today
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Amgen, Inc. (AMGN): Is Galena Biopharma Inc (GALE)’s Big Break Just Around the Corner?
Judging by the numbers, Galena Biopharma Inc (NASDAQ:GALE) isn't exactly a stock many would call great.
Amgen, Inc. (AMGN) and Onyx Pharmaceuticals, Inc. (ONXX): Half a Billion Dollars’ Worth of Drama
A finale has at last arrived for the biotech drama of summer 2013. Amgen, Inc. (NASDAQ:AMGN) announced yesterday that it will buy Onyx Pharmaceuticals, Inc.
What Is Amgen, Inc. (AMGN) Getting For Its Money?
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Pfizer Inc. (PFE), Amgen, Inc. (AMGN), UnitedHealth Group Inc. (UNH): Do Health Care Stocks Fall in the Fall?
Every investor has heard the old line "sell in May and go away." That wasn't such great advice this year with the S&P 500 index up nearly 5% since the beginning of May.
Hedge Funds Are Buying Amgen, Inc. (AMGN)
To the average investor, there are tons of metrics shareholders can use to analyze stocks. Some of the most innovative are hedge fund and insider trading activity.
Amgen, Inc. (AMGN), AstraZeneca plc (ADR) (AZN): What’s the Big Deal About Onyx Pharmaceuticals, Inc. (ONXX) Anyway?
At the end of June, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) announced that it had rejected an offer from Amgen, Inc.
This Biogen Idec Inc. (BIIB) Data is Screaming ‘Buy, Buy, Buy’
To many market players, hedge funds are assumed to be overrated, old investment vehicles of a forgotten age.
Medivation Inc (MDVN), Seattle Genetics, Inc. (SGEN) – Biotech Buyouts: Who’s Next?
There's been plenty of buzz lately about the continuing saga of the possible buyout of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) by Amgen, Inc. (NASDAQ:AMGN).
Pharma News: Vivus, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)’s Settled Stock & Amgen, Inc. (AMGN)’s Clinical Trial
Investors in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) saw new options become available this week, for the April 2014 expiration. ...VIVUS, Inc.
Is Celgene Corporation (CELG) Going to Burn You?
To many traders, hedge funds are perceived as overrated, outdated investment tools of a forgotten age.
Green Mountain Coffee Roasters Inc. (GMCR), Gilead Sciences, Inc. (GILD): Investing in Quality Stocks — Made Easy
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Novartis AG (ADR) (NVS), Amgen, Inc. (AMGN): Incyte Corporation (INCY) Jumps on Jakafi Results
Incyte Corporation (NASDAQ:INCY) today announced positive results from a phase 2 study of its drug Jakafi in treating refractory metastatic pancreatic cancer.
Pfizer Inc. (PFE), Regeneron Pharmaceuticals Inc (REGN): Are These Drugs the Future of High-Cholesterol Treatment?
Once upon a time in a regulatory environment far, far away, there was a cholesterol-fighting drug named Lipitor from Pfizer Inc. (NYSE:PFE).
Pharma News: VIVUS, Inc. (VVUS)’s Injury, Arena Pharmaceuticals, Inc. (ARNA) & Amgen, Inc. (AMGN)’s Agreement
The ratings of four Pharmaceutical stocks are down this week, according to the Portfolio Grader database.
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN), Alexion Pharmaceuticals, Inc. (ALXN): Biotech’s Falling Fortunes Stymie Osiris Therapeutics, Inc. (OSIR)’s Huge Week
Biotech's the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts...
Pharma News: VIVUS, Inc. (VVUS) Qsymia Patents, Arena Pharmaceuticals, Inc. (ARNA) Earnings, Amgen, Inc. (AMGN) Ending an Agreement
Earlier today RFD IP Business Services ("RFD") released a new report analyzing the likely inequitable conduct challenges to VIVUS, Inc.
Amgen, Inc. (AMGN), Corning Incorporated (GLW): Top Stocks Growing Their Dividends By 25% Per Year
Dividend investors would be wise to focus not just on a stock's current yield, but also on the long-term growth potential of its dividends.
GlaxoSmithKline plc (ADR) (GSK), Roche Holding Ltd. (ADR) (RHHBY): Why Alex Rodriguez Could Bring Big Business to This Sector
Baseball star Alex Rodriguez had an opportunity to be perhaps the greatest player of the past decade or even longer -- that was until he threw it all away by admitting to steroid...
Amgen, Inc. (AMGN), Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): A Closer Look at the Battle Over Cancer Treatments
Over the past year, the battle over cancer treatments has heated up considerably. Big pharma companies such as Amgen, Inc. (NASDAQ:AMGN), Pfizer Inc.
Aegerion Pharmaceuticals, Inc. (AEGR), ISIS Pharmaceuticals, Inc. (ISIS), Sanofi SA (ADR) (SNY): This Is One Incredible CEO
The Motley Fool's readers have spoken, and I have heeded their cries.
Pfizer Inc. (PFE), Amgen, Inc. (AMGN): The Best-Selling Medications of 2013 (So Far)
Believe it or not, 2013 is getting close to being two-thirds of the way over. Many pharmaceutical firms have enjoyed great stock returns and nice profits thus far in the year.
3 Things You Need to Know From Vical Incorporated (VICL)’s Q2 Results
Vical Incorporated (NASDAQ:VICL) announced its second-quarter results on Thursday.
Amgen, Inc. (AMGN), Baxter International Inc. (BAX): Can the FDA Make Up Its Mind Already?
It isn't very often that an agency sometimes accused of over-regulating an industry can be ridiculed for not regulating enough, but that's exactly where the Food and Drug Administration...
Three Things You Need to Know From Keryx Biopharmaceuticals (KERX)’s Q2 Earnings
Keryx Biopharmaceuticals (NASDAQ:KERX) announced its second-quarter results before the market opened on Thursday.
Is More Patent Pain Headed Merck & Co., Inc. (MRK)’s Way?
Merck & Co., Inc. (NYSE:MRK) might be one of big pharma's largest companies, but this health care leader has had a tough go recently.
Pharma News: Vivus, Inc. (VVUS)’s New CEO, Arena Pharmaceuticals, Inc. (ARNA) & Amgen, Inc. (AMGN)’s Positive Earnings
VIVUS, Inc. (NASDAQ:VVUS), which sells the obesity drug Qsymia, has appointed Anthony Zook to serve as its CEO.
